These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25017687)

  • 21. Evolution of iv iron compounds over the last century.
    Macdougall IC
    J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures.
    Nathell L; Gohlke A; Wohlfeil S
    Drug Saf; 2020 Jan; 43(1):35-43. PubMed ID: 31583644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaphylactoid reaction to intravenous sodium ferric gluconate complex during pregnancy.
    Cuciti C; Mayer DC; Arnette R; Spielman FJ
    Int J Obstet Anesth; 2005 Oct; 14(4):362-4. PubMed ID: 16140521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A successful protocol for desensitization to iron salts.
    Terzioglu K; Epöztürk K
    Indian J Pharmacol; 2021; 53(4):332-333. PubMed ID: 34414914
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of parenteral iron products and serious anaphylactic-type reactions.
    Wysowski DK; Swartz L; Borders-Hemphill BV; Goulding MR; Dormitzer C
    Am J Hematol; 2010 Sep; 85(9):650-4. PubMed ID: 20661919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
    Blumenstein I; Shanbhag S; Langguth P; Kalra PA; Zoller H; Lim W
    Expert Opin Drug Saf; 2021 Jul; 20(7):757-769. PubMed ID: 33993818
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug allergy in pediatric patients.
    Abonia JP; Castells M
    Pediatr Ann; 2011 Apr; 40(4):200-4. PubMed ID: 21485996
    [No Abstract]   [Full Text] [Related]  

  • 29. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy.
    Khalafallah A; Dennis A; Bates J; Bates G; Robertson IK; Smith L; Ball MJ; Seaton D; Brain T; Rasko JE
    J Intern Med; 2010 Sep; 268(3):286-95. PubMed ID: 20546462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid iron desensitization after generalized urticaria and facial angioedema.
    Rodríguez-Jiménez B; Domínguez-Ortega J; Nuñez-Acevedo B; Cava-Sumner B; Kindelan-Recarte C; Montojo-Guillén C
    J Investig Allergol Clin Immunol; 2014; 24(1):69-71. PubMed ID: 24765889
    [No Abstract]   [Full Text] [Related]  

  • 31. Approach to the patient with drug allergy.
    Schnyder B
    Med Clin North Am; 2010 Jul; 94(4):665-79, xv. PubMed ID: 20609856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on adverse drug events associated with parenteral iron.
    Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
    Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
    Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
    Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prophylactic problems of drug allergy].
    Novikov VS; Chernyshev VA; Martynov VI; Komarov VA; Zubok NM
    Voen Med Zh; 1986 Sep; (9):57-8. PubMed ID: 3798814
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
    Michael B; Fishbane S; Coyne DW; Agarwal R; Warnock DG
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):92-100. PubMed ID: 16932400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse reaction to intravenous iron: hypersensitivity or secondary side effect?
    Sirvent-Pedreño AE; Enríquez-Ascarza R; Redondo-Pachón MD; Millán-del Valle I; González-Martinez C; Amorós-Amorós F
    Nefrologia; 2013 Jan; 33(1):148-9. PubMed ID: 23364652
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
    Trumbo H; Kaluza K; Numan S; Goodnough LT
    Drug Saf; 2021 Jan; 44(1):107-119. PubMed ID: 33237523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
    Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
    Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.